Everything you need to win Ascendis Pharma A/S and Royalty Pharma plc — in one platform.
Who to reach, what to say, and why now on Ascendis Pharma A/S and Royalty Pharma plc — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on Ascendis Pharma A/S and Royalty Pharma plc — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
The decision-maker’s email and mobile — dial in-browser.
Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement
Sep 03, 2024•almost 2 years ago
Contract Type
agreement
BiotechnologyPharmaceuticalBiopharma
Description
Ascendis Pharma A/S and Royalty Pharma plc have entered into a $150 million capped synthetic royalty funding agreement, where Ascendis Pharma receives an upfront payment of $150 million in exchange for a 3% royalty on U.S. net sales of YORVIPATH, the first and only FDA approved treatment of hypoparathyroidism in adults. This agreement reflects the significant value of YORVIPATH and the commitment to reduce the cost of capital while maintaining flexibility to support global commercial capabilities.
Company Information
Company
Ascendis Pharma A/S and Royalty Pharma plc
About
Ascendis Pharma A/S is a biopharmaceutical company based in Denmark, while Royalty Pharma plc is a leading funder of innovation across the biopharma industry based in New York.
Predictive Intelligence
Strategic
ML-powered predictions for Ascendis Pharma A/S and Royalty Pharma plc's next move
